EUVIMEDObjevte EUVIMED
Multizentrische StudieBeobachtungsstudie

Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting

Lionel Falchero, Nicolas Meyer, Olivier Molinier, Faraj Al Freijat, Hervé Pegliasco, Emmanuelle Lecuyer, Luc Stoven, Laure Belmont, Sandrine Loutski, Cécile Maincent, Anne-Sophie Blanchet-Legens, Alexa Mairovitz and 5 more

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114277 ↗

At a glance

Multizentrische Studie in European Journal of Cancer, 2024. Written by Lionel Falchero and 16 co-authors. Institution: Respiratory Medicine Department, Hopitaux Nord-Ouest, Villefranche-Sur-Saône, France. Electronic address: lfalchero@hno.fr. Major MEDLINE topics: Immunotherapy, Lung Neoplasms, Small Cell Lung Carcinoma. Cited 12 times so far (Crossref); 24 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

BACKGROUND: The KBP studies are real-life nationwide, prospective, multicenter cohort studies of patients diagnosed with primary lung cancer that have been conducted in French non-academic public hospitals each decade since 2000. METHODS: Patients were analyzed in three prospective cohorts using the same methodology. In this study, we describe and compare the characteristics and outcomes of patients with small cell lung cancer (SCLC), with a focus on treatments in the 2020 cohort. FINDINGS: 8999 patients with lung cancer were included in the 2020 cohort, of whom 1137 had SCLC. From 2000 to 2010 and 2020, the proportion of patients with SCLC decreased from 16.4 % to 13.5 % and 12.6 % respectively. Between 2000 and 2020, the proportion of women increased from 15.5 % to 35.7 %. 15.4 % of patients with SCLC had limited-stage (LS) disease and 84.6 % of patients had extensive-stage (ES) disease. The 1-year overall survival (OS) rate for all patients with SCLC increased from 34.4 % in 2000 to 38.4 % in 2020. For ES-SCLC, multivariate analysis weighted with "entropy balancing" by including age, sex, performance status, number of metastatic sites, and brain metastases indicated an improvement in median OS from 8.1 months in patients receiving chemotherapy only to 11.1 months in patients receiving chemotherapy plus immunotherapy (HR 0.62, p < 0.001). INTERPRETATION: The proportion with SCLC has decreased over time, but the proportion of women has increased. The 1-year OS rates have improved over 20 years. The KBP-2020 cohort suggests a benefit of immunotherapy on OS in patients with ES-SCLC in the real-life setting.

Subjects

MeSH terms (MEDLINE)

ImmunotherapyLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedFranceProspective StudiesSurvival RateTime FactorsTreatment Outcome

Author keywords

ChemoradiotherapyChemotherapyImmunotherapyNon-academic public hospitalRadiotherapyReal-world dataSmall cell lung cancer

Authors and institutions

  • Respiratory Medicine Department, Hopitaux Nord-Ouest, Villefranche-Sur-Saône, France. Electronic address: lfalchero@hno.fr.
  • Public Health Department, CHU de Strasbourg, GMRC, Strasbourg, France.
  • Respiratory Medicine Department, Centre Hospitalier Le Mans, Le Mans, France.
  • Respiratory Medicine Department, Hôpital Nord Franche-Comté, Belfort, France.
  • Respiratory Medicine Department, Hôpital Européen Marseille, Marseille, France.
  • Respiratory Medicine Department, Centre Hospitalier de Saint-Quentin, Saint-Quentin, France.

Cite

APA

Falchero, L., Meyer, N., Molinier, O., Al Freijat, F., Pegliasco, H., Lecuyer, E., Stoven, L., Belmont, L., Loutski, S., Maincent, C., Blanchet-Legens, A. S., Mairovitz, A., Meniai, F., Hominal, S., Letierce, A., Morel, H., & Debieuvre, D. (2024). Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114277

Vancouver

Falchero L, Meyer N, Molinier O, Al Freijat F, Pegliasco H, Lecuyer E, et al. Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114277

BibTeX
@article{Falchero2024,
  author = {Falchero, Lionel and Meyer, Nicolas and Molinier, Olivier and Al Freijat, Faraj and Pegliasco, Hervé and Lecuyer, Emmanuelle and Stoven, Luc and Belmont, Laure and Loutski, Sandrine and Maincent, Cécile and Blanchet-Legens, Anne-Sophie and Mairovitz, Alexa and Meniai, Fatima and Hominal, Stéphane and Letierce, Alexia and Morel, Hugues and Debieuvre, Didier},
  title = {Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114277}
}
Start for free →